Using a single blood sample, multi-cancer early detection (MCED) tests screen for numerous types of cancers, including breast, ovarian, colorectal, pancreatic and prostate cancers. Trials are underway ...
Multicancer early detection (MCED) assays use circulating tumor DNA, methylation patterns, RNA, and protein biomarkers to detect multiple cancer types early, potentially revolutionizing cancer ...
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and ...
The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That’s the thesis behind SpotitEarly, a startup that recently launched in the ...
The Cancer Check blood test screens for more than 200 types of solid tumor cancers and has detected cancer before symptoms appear, as early as Stage 0, when there is a 99% survival rate. The addition ...
MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with ...
SEOUL, Korea and MENLO PARK, Calif., Oct. 16, 2025 /PRNewswire/ -- Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of ...
Sentara Health is recruiting Hampton Roads and Charlottesville residents for the Cancer Screening Research Network’s national Vanguard Study, which assesses the feasibility of using multicancer ...
Early cancer often develops silently, making late detection harder to treat and deadlier. Experts recommend four key ...
The discovery began, as many breakthroughs do, with an observation that didn’t quite make sense. In 1948, two French researchers, Paul Mandel and Pierre Métais, published a little-noticed paper in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback